Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SCORE2-Diabetes

- PMLiVE

Novo Nordisk announces positive phase 2 trial results for type 2 diabetes treatment

More than 4.9 million people in the UK have diabetes, around 90% of which have type 2 diabetes

- PMLiVE

Lilly showcases tirzepatide type 2 diabetes data at ADA 2021

Company is planning to submit the full data package for tirzepatide to regulatory authorities by the end of 2021

- PMLiVE

Novo Nordisk reveals positive results at ADA 2021 for higher-dose Ozempic in type 2 diabetes

Ozempic 2 mg demonstrated a 2.2% reduction in blood sugar compared with a 1.9% reduction for those receiving Ozempic 1 mg

- PMLiVE

Lilly’s tirzepatide shows superiority over Novo’s semaglutide in type 2 diabetes trial

Lilly's drug beat semaglutide 1mg on multiple measures including weight loss

- PMLiVE

Cambridge University develops DNA test for secondary infections in COVID-19 patients

Test can identify cases of ‘ventilator-associated pneumonia’

- PMLiVE

World Diabetes Day 2019

Many lack knowledge around type 2 diabetes risk factors, says new survey

AstraZeneca AZ

AZ’s Farxiga gets heart failure prevention okay from FDA

Important win for AZ as it chases down market leader Jardiance

- PMLiVE

Novo uses voucher for speedy answer on oral semaglutide

Oral version of Ozempic could be diabetes market leader

- PMLiVE

23andMe to offer type 2 diabetes testing kit

New report is powered by data from the company’s customers

- PMLiVE

Roche offers diabetes digital health programme to UK patients

Partners with OurPath for its six-week lifestyle management programme

- PMLiVE

Heart research campaign urges chocolate detox for workers

British Heart Foundation hopes to inspire officer workers to abstain in March

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links